Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma
- PMID: 20655738
- PMCID: PMC2987546
- DOI: 10.1016/j.ejca.2010.06.129
Promoter polymorphisms in matrix metallopeptidase 1 and risk of cutaneous melanoma
Abstract
Matrix metallopeptidase 1 (MMP1) is one of the interstitial collagens in the extracellular matrix metalloproteinase family and involved in tumour behaviours. However, there is no report on the role of genetic variation in MMP1 in risk of cutaneous melanoma (CM). We investigated the association between genotypes and haplotypes of seven reported MMP1 promoter polymorphisms [-1607G ins/del (2G/1G), -839G>A, -755T>G, -519A>G, -422A>T, -340A>G and -320T>C, genotyped by the TaqMan assay] and CM risk in 872 patients and 873 cancer-free controls. These seven polymorphisms were not in linkage disequilibrium among each other (r(2)<0.63). Compared to their common homozygous genotypes, the variant -519GG was associated with significantly decreased CM risk [adjusted odds ratio (OR)=0.71, 95% confidence interval (CI)=0.52-0.99], whereas variants -422TT and -320CC were associated with significantly increased CM risk (OR=1.50, 95% CI=1.11-2.03 and OR=1.72, 95% CI=1.05-2.81, respectively) after adjustment for age, sex, family history and sun-exposure-related risk factors. The number of risk alleles of these three polymorphisms was associated with CM risk in a dose-response manner (P(trend)=0.0002). In the stratification analysis, we found that the associations of these polymorphisms with CM risk were modified by some of the risk factors. Furthermore, the haplotypes Gdel-A-G-A-T-G-T and G-G-G-A-T-A-T were associated with significantly increased CM risk (ORs=1.56 and 2.13, 95% CIs=1.02-2.38 and 1.22-3.70, respectively). These findings suggest that MMP1 promoter polymorphisms may individually or jointly play roles in the development of CM.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Conflict of interest statement: None declared.
Figures
Similar articles
-
A Matrix Metalloproteinase-1 Polymorphism, MMP1-1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients.Dis Markers. 2018 Dec 2;2018:7565834. doi: 10.1155/2018/7565834. eCollection 2018. Dis Markers. 2018. PMID: 30627228 Free PMC article. Review.
-
Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.Melanoma Res. 2012 Apr;22(2):169-75. doi: 10.1097/CMR.0b013e32834fc46b. Melanoma Res. 2012. PMID: 22198560 Free PMC article.
-
Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma.Hum Mutat. 2008 Dec;29(12):1443-51. doi: 10.1002/humu.20803. Hum Mutat. 2008. PMID: 18563783 Free PMC article.
-
The Association of Matrix Metalloproteinase-1 Promoter Polymorphisms with Breast Cancer.In Vivo. 2018 May-Jun;32(3):487-491. doi: 10.21873/invivo.11265. In Vivo. 2018. PMID: 29695550 Free PMC article.
-
Association of a haplotype of matrix metalloproteinase (MMP)-1 and MMP-3 polymorphisms with renal cell carcinoma.Carcinogenesis. 2004 Dec;25(12):2379-84. doi: 10.1093/carcin/bgh254. Epub 2004 Aug 19. Carcinogenesis. 2004. PMID: 15319295
Cited by
-
A Matrix Metalloproteinase-1 Polymorphism, MMP1-1607 (1G>2G), Is Associated with Increased Cancer Risk: A Meta-Analysis Including 21,327 Patients.Dis Markers. 2018 Dec 2;2018:7565834. doi: 10.1155/2018/7565834. eCollection 2018. Dis Markers. 2018. PMID: 30627228 Free PMC article. Review.
-
Influence of single nucleotide polymorphisms in the MMP1 promoter region on cutaneous melanoma progression.Melanoma Res. 2012 Apr;22(2):169-75. doi: 10.1097/CMR.0b013e32834fc46b. Melanoma Res. 2012. PMID: 22198560 Free PMC article.
-
Identification and vitro verification of the potential drug targets of active ingredients of Chonglou in the treatment of lung adenocarcinoma based on EMT-related genes.Front Genet. 2023 Feb 7;14:1112671. doi: 10.3389/fgene.2023.1112671. eCollection 2023. Front Genet. 2023. PMID: 36824434 Free PMC article.
-
The relationship between single nucleotide polymorphisms and skin cancer susceptibility: A systematic review and network meta-analysis.Front Oncol. 2023 Feb 15;13:1094309. doi: 10.3389/fonc.2023.1094309. eCollection 2023. Front Oncol. 2023. PMID: 36874118 Free PMC article.
-
Relationship of long-term prognosis to MMP and TIMP polymorphisms in patients after ST elevation myocardial infarction.J Appl Genet. 2017 Aug;58(3):331-341. doi: 10.1007/s13353-016-0388-8. Epub 2017 Jan 18. J Appl Genet. 2017. PMID: 28101856
References
-
- Cummins DL, Cummins JM, Pantle H, et al. Cutaneous malignant melanoma. Mayo Clin Proc. 2006;81(4):500–7. - PubMed
-
- Goldstein AM, Tucker MA. Genetic epidemiology of cutaneous melanoma: a global perspective. Arch Dermatol. 2001;137(11):1493–6. - PubMed
-
- Ries LAG, Eisner MP, Kosary CL, et al. National Cancer Institute; Bethesda, MD: 2003. SEER Cancer Statistics Review, 1975-2000. http://seer.cancer.gov/csr/1975_2000/
-
- Leiter U, Garbe C. Epidemiology of melanoma and nonmelanoma skin cancer--the role of sunlight. Adv Exp Med Biol. 2008;624:89–103. - PubMed
-
- Karim-Kos HE, de Vries E, Soerjomataram I, et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345–89. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical